Report Highlights

Smart Insulin Pens in the United States: Market Overview

The U.S. smart insulin pen market was valued at USD 0.92 billion in 2024 and is forecast to reach USD 2.18 billion by 2032. Market structure is oligopolistic: Eli Lilly and Novo Nordisk control most insulin volume and supply the pens on which connected hardware is built, while Companion Medical's InPen and Novo Nordisk's NovoPen Echo Plus occupy the Bluetooth-enabled niche. Private manufacturers have driven product innovation, while government has set the commercial frame through Medicare benefit design and FDA clearance pathways.

Government has been the dominant force in pricing and reimbursement rather than manufacturing. The Centers for Medicare and Medicaid Services administers Part D benefit design, and the Food and Drug Administration's Center for Devices and Radiological Health classifies smart pen hardware and companion software. State legislatures have added commercial protection, most notably Colorado's HB19-1218, which capped insulin copayments at USD 100 per 30-day supply and served as a template for later state caps.

Policy-Driven Growth in U.S. Smart Insulin Pens

Three federal mechanisms are driving demand. First, Section 11406 of the Inflation Reduction Act caps Medicare Part D insulin out-of-pocket costs at USD 35 per month from January 1, 2023, keeping beneficiaries on pen therapy rather than switching to vials and expanding the installed base of pen users. Second, CMS remote patient monitoring codes CPT 99453, 99454 and 99457 reimburse device setup, supply and clinician review, converting smart pen dose data into billable services for physician practices.

Third, the Medicare Drug Price Negotiation Program under the same Act set negotiated prices for insulin aspart products, including NovoLog and Fiasp, effective January 1, 2026. Lower drug prices compress manufacturer margins and push companies toward device-linked adherence programmes that justify premium pen hardware. FDA's final Predetermined Change Control Plan guidance, issued in December 2024, further lets manufacturers update pen software without new 510(k) submissions, accelerating feature releases.

Regulatory Barriers and Compliance Costs

The primary barrier is FDA premarket clearance. Most connected pens and add-on caps enter through the 510(k) pathway under the Federal Food, Drug, and Cosmetic Act, administered by the Center for Devices and Radiological Health and funded through MDUFA V user fees. The Quality Management System Regulation at 21 CFR Part 820, aligned with ISO 13485:2016 and effective February 2, 2026, adds design control documentation to every product revision. Section 524B cybersecurity requirements demand a software bill of materials and patch-management plans for each connected device.

Import costs form a second barrier. USTR's Section 301 action set a 100 percent tariff on Chinese-origin syringes and needles from September 27, 2024, raising landed cost for pen needles that Customs and Border Protection classifies under the same headings. Data handling adds compliance cost: the Health Breach Notification Rule, amended by the Federal Trade Commission in 2024, requires notification when pen apps disclose health data outside HIPAA, while HHS Office for Civil Rights enforces HIPAA Security Rule obligations at 45 CFR Parts 160 and 164.

Policy-Created Opportunities in the United States

The CY2025 Medicare Physician Fee Schedule added CPT 99445 for remote monitoring over two to 15 days, creating a reimbursable pathway for short-term insulin titration monitoring that smart pen vendors can target. The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) requires payers to deploy patient access APIs by January 1, 2027, opening demand for integration services that link pen dose logs to payer and electronic health record systems.

Federal procurement offers a second channel. The Department of Veterans Affairs buys insulin and diabetes devices through Federal Supply Schedule contracts and its national formulary, and TRICARE pharmacy benefits cover pen-based insulin for military beneficiaries. Companies that bundle connected pens with clinical monitoring under these contracts secure volume commitments that commercial payers have not yet offered at scale.

Market at a Glance

Leading Market Participants

• Eli Lilly and Company
• Novo Nordisk
• Sanofi
• Companion Medical
• Medtronic
• Dexcom
• Abbott
• Insulet
• Ypsomed
• Owen Mumford

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, with Section 524B added by the Consolidated Appropriations Act, 2023, and the Medical Device User Fee Amendments reauthorised under the FDA Reauthorization Act of 2022 (MDUFA V, covering fiscal years 2023 to 2027). The Food and Drug Administration supervises clearance; the Centers for Medicare and Medicaid Services governs reimbursement; the Office of the National Coordinator for Health Information Technology enforces information-blocking rules under 45 CFR Part 171; and the Federal Trade Commission enforces the Health Breach Notification Rule.

Key dates are fixed. MDUFA VI negotiations must conclude before the current programme expires on September 30, 2027, the CMS-0057-F payer API deadline arrives January 1, 2027, and negotiated insulin aspart prices took effect January 1, 2026. Compared with regional peers, the U.S. 510(k) pathway clears connected pens faster than the EU Medical Device Regulation (EU) 2017/745, which requires notified-body certification, while Health Canada's Medical Devices Regulations (SOR/98-282) require a licence for Class II devices with comparable documentation demands.

Long-Term Policy Outlook for U.S. Smart Insulin Pens

Changes expected by 2032 will centre on interoperability and reimbursement. Information-blocking enforcement will require pen manufacturers to expose dose data through standardised FHIR interfaces, reshaping market entry for vendors without electronic health record integration. The Medicare Drug Price Negotiation Program will extend to additional insulin products in later selection cycles, compressing list-price revenue and shifting competition toward device-linked adherence services.

FDA's Predetermined Change Control Plan framework will shorten software release cycles for pen applications and reduce per-update clearance costs. FTC enforcement of the amended Health Breach Notification Rule will tighten consent and data-sharing standards for non-HIPAA pen apps, while Section 301 tariffs will keep pushing needle and cartridge production toward domestic facilities. These forces will move the market from hardware-led to data-service revenue models.